Stock Market Reviews

Read and share opinions on CELC (Celcuity Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Celcuity CEO Sets July 17 PDUFA for Gedatolisib, Teases VIKTORIA-1 Mutant Data at Conference
  Celcuity (NASDAQ:CELC) CEO Brian Sullivan outlined the company’s expected regulatory timeline and commercial preparations for gedatolisib during an appearance at the Guggenheim Healthcare Conference, while also previewing upcoming clinical catalysts and how the company views the therapy’s positionin
  Feb 12, 2026
• Celcuity Appoints Charles Romp to its Board of Directors
  MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of Directors. Mr. Romp brings over 25 years of experience in the pharmaceutical industry to Celcuity, including leadership of sales teams and commercial organizations in the oncology setting. “Chip brings a wealth of oncology-related commercial expertise t
  Feb 12, 2026
• Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump
  Focused on targeted cancer therapies, this biotech firm reported a notable insider sale amid a year of extraordinary stock performance.
  Feb 6, 2026
• Assessing Celcuity (CELC) Valuation After Recent Share Price Momentum And DCF Upside Estimate
  Celcuity (CELC) has been drawing fresh attention after recent share price moves, with the stock up around 45% over the past 3 months and modestly higher over the past month. See our latest analysis for Celcuity. That sharp 45% 3 month share price return sits alongside a 7% year to date gain, while the very large 1 year total shareholder return suggests strong momentum. However, the recent 7 day and 1 day share price declines hint at some cooling in the short term. If Celcuity’s move has you...
  Feb 5, 2026
• Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026
  MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 to be held in New York, New York on February 11-12, 2026. Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, is scheduled for a fireside chat at 9:30 a.m. ET on Wednesday, February 11, 2026. A live webcast of the event w
  Feb 4, 2026
• Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors
  We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Relay Therapeutics, Inc. (NASDAQ:RLAY) is the next best biotech stock on our list. TheFly reported on January 26 that Oppenheimer upgraded RLAY from Perform to Outperform and set a $14 price target. The firm said the upcoming VIKTORIA-1 trial […]
  Feb 2, 2026
• Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances
  Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 investor letter. A copy of the letter can be downloaded here. Apis Flagship Fund delivered strong performance in the fourth quarter of 2025, with the Fund up 10.0% net for the quarter and gaining 55.1% for the full year, significantly outperforming the MSCI ACWI global […]
  Feb 2, 2026
• Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year?
  Here is how Cabaletta Bio, Inc. (CABA) and Celcuity, Inc. (CELC) have performed compared to their sector so far this year.
  Jan 27, 2026
• Reassessing Celcuity (CELC) Valuation After A 51.85% Three Month Share Price Gain
  Celcuity (CELC) has been drawing attention after a period of strong recent returns, including a gain over the past 3 months, prompting investors to reassess the clinical stage biotech’s risk and reward profile. See our latest analysis for Celcuity. At a share price of $107.16, Celcuity’s recent 51.85% 3 month share price return sits alongside a very large 1 year total shareholder return, which suggests investors have been rapidly repricing its prospects and risk profile. If Celcuity’s move...
  Jan 22, 2026
• Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
  FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026 MINNEAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for filing its New Drug Application (“NDA”) for gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), PIK3CA wild-ty
  Jan 20, 2026
• Wells Fargo Initiates Coverage On Celcuity Inc. (CELC)
  Celcuity Inc. (NASDAQ:CELC) is among the 20 Best Performing Stocks in 2025. On December 12, 2025, TheFly reported that Wells Fargo started covering Celcuity Inc. (NASDAQ:CELC) with a $126 price target and an Overweight rating. According to the firm, Phase 1 data and results from the wild-type cohort have significantly reduced the risk associated with […]
  Jan 11, 2026
• Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase?
  CELC shares surge as NDA filing and strong phase III data boost optimism around gedatolisib's potential.
  Jan 6, 2026
• Celcuity (CELC) Surges 662% in 2025 on Breast Cancer Treatment Trial Results
  We recently published 10 Market Stars Behind Millionaire-Making in 2025. Celcuity Inc. (NASDAQ:CELC) is one of the top performers. Celcuity climbed by 661.96 percent in 2025, with the overall rally primarily fueled by strong results from the phase 3 clinical trial of its treatment candidate for breast cancer. In an updated report which was presented […]
  Jan 2, 2026
• How Investors Are Reacting To Celcuity (CELC) Gedatolisib’s Phase 3 Breast Cancer Data And Safety Profile
  In December 2025, Celcuity Inc. reported updated Phase 3 VIKTORIA-1 trial results at the San Antonio Breast Cancer Symposium, showing gedatolisib-based regimens improved progression-free survival and quality-of-life measures versus fulvestrant alone in certain patients with advanced HR+/HER2- breast cancer. An interesting aspect for investors is that gedatolisib appeared to avoid clinically relevant hyperglycemia, a frequent issue with some PI3K-pathway drugs, while maintaining efficacy in...
  Dec 17, 2025
• Celcuity (CELC): Fresh Phase 3 Breast Cancer Data Prompts Closer Look at Gedatolisib-Driven Valuation
  Celcuity (CELC) just put fresh Phase 3 VIKTORIA-1 data for gedatolisib in front of oncologists at the San Antonio Breast Cancer Symposium, sharpening the picture around efficacy, safety, and real world quality of life. See our latest analysis for Celcuity. The latest VIKTORIA-1 update lands after an explosive run, with Celcuity’s 90 day share price return of around 84% and 1 year total shareholder return close to 700%, signaling strong, momentum driven optimism around gedatolisib’s...
  Dec 17, 2025
• 5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
  MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors
  Dec 16, 2025
• Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
  For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival (“PFS”) was 12.4 months with gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and 10.0 months with gedatolisib + fulvestrant (“gedatolisib doublet”) versus 1.9 months for fulvestrantFor patients enrolled in the U.S., Canada, Western Europe, and Asia Pacific, median PFS was 16.6 months with the gedatolisib triplet and 7.1 months with the gedatolisib doublet versus 1.9
  Dec 11, 2025
• 3 Stocks You’ll Wish You Bought Before 2026
  These three up-and-coming stocks are delivering massive 2025 gains and may have more room to run as key catalysts unfold
  Dec 3, 2025
• Celcuity Stock Near All-Time Highs — And This Major Biotech Investor Is Still Jumping In
  A top biotech fund just made a bold move while Celcuity trades near record highs—here’s what they might see coming next.
  Dec 2, 2025
• Celcuity (CELC): Assessing Valuation Following Recent Share Price Surge
  Celcuity (CELC) shares have climbed higher in the past month, outpacing many biotech peers. Investors are watching closely as the company focuses on therapies targeting solid tumors. Recent returns have shown renewed market interest. See our latest analysis for Celcuity. Celcuity’s momentum keeps building, with a 1-month share price return of nearly 37% and a remarkable 90-day jump of 97%. Over the past year, investors have seen a stunning 690% total shareholder return as market enthusiasm...
  Nov 29, 2025

• BuyTheDipBro

  Feb 13, 2026

  $CELC They cookin' somethin' real nice, vibes are strong!

  Buy

• EquityEnigma

  Feb 12, 2026

  $CELC The advancements are exciting, but there’s an electric tension swirling around the market response—are we on the brink of something huge or headed for trouble?

  Buy

• ShortSqueezeX

  Feb 12, 2026

  $CELC If this company had a motto, it would be, 'Cell-ebration of innovation, one cell at a time!'

  Buy

• EquityAssault

  Feb 11, 2026

  $CELC A classic case of too much hype for too little substance.

  Sell

• ProfitLancer

  Feb 10, 2026

  $CELC This one’s in the limelight but lacks the shine.

  Sell

• TradeProtocol

  Feb 10, 2026

  $CELC Like that one friend who insists they can cook but only makes microwave popcorn—potential is there, but watch out for burnt kernels!

  Sell

• TradeReckoner

  Feb 9, 2026

  $CELC This one is as exciting as a lukewarm cup of water.

  Sell

• MarketMyth

  Feb 8, 2026

  $CELC This organization is at the forefront of developing groundbreaking treatments for serious diseases, showcasing an impressive pipeline that holds promise for significant future growth and innovation in the healthcare sector.

  Buy

• TrendStalker

  Feb 8, 2026

  $CELC An underwhelming player in an already crowded field.

  Sell

• PortfolioGremlin

  Feb 7, 2026

  $CELC This little player’s got the smarts, ready to make moves!

  Buy

• RiskReaper

  Feb 7, 2026

  $CELC This biotech company is making strides in research and development, focusing on innovative solutions that address unmet medical needs. Its commitment to science and improvement in patient outcomes could resonate well in the market.

  Buy

• CapitalCreep

  Feb 6, 2026

  $CELC With numbers like these, they should consider a different industry.

  Sell

• ByteBull

  Feb 5, 2026

  $CELC Like a puzzle with a missing piece, this stock has me scratching my head. Is it genius or just missing the mark?

  Sell

• TradeBlitz

  Feb 4, 2026

  $CELC If cells had a party, they'd probably call it a Cell-ebrate! Get it?

  Buy

• TrendScript

  Feb 4, 2026

  $CELC This company’s unique approach to tackling cancer therapies reflects a strong potential to impact the medical landscape. With increasing attention to precision medicine, its advancements could position it favorably for long-term growth.

  Buy

• MarketRender

  Feb 4, 2026

  $CELC With promising signals in recent data, excitement is high, but the volatility of biotech stocks creates a whirlpool of uncertainty. Will this momentum hold, or is it just a mirage?

  Buy

• DigitalDividend

  Feb 4, 2026

  $CELC Think of them as the detective in a mystery novel, uncovering secrets one cell at a time, but way more science-y!

  Buy

• PortfolioFreak

  Feb 4, 2026

  $CELC The potential here is immense, but heavy reliance on their lead product makes them vulnerable. One miscalculation, and the dream could quickly unravel. Can they sustain this momentum?

  Sell

• TradeNinja

  Feb 4, 2026

  $CELC This company's got more twists than a soap opera! Tune in next week to see if it’s a cliffhanger or a happy ending.

  Buy

• StonkRider

  Feb 3, 2026

  $CELC This innovative company is making strides in the biotechnology sector, focusing on the development of targeted therapies that address significant unmet medical needs. Their novel approach has the potential to reshape treatment paradigms and deliver substantial benefits to patients.

  Buy

• TradingNomad

  Feb 3, 2026

  $CELC With the biotech world buzzing with innovation, this company's potential feels like a thrilling yet nerve-wracking lottery—what will come next?

  Buy

• WallStreetVandal

  Feb 3, 2026

  $CELC Good luck finding someone who cares about this one.

  Sell

• BearishBoi

  Feb 2, 2026

  $CELC This stock has more twists than a rom-com plot—will it end happily or lead us to heartbreak?

  Sell

• CashCombo

  Feb 1, 2026

  $CELC If testing new drugs was a video game, these folks would be the final boss—seriously, they're leveling up patient care!

  Buy

• EarningsEcho

  Feb 1, 2026

  $CELC This stock is the overachiever in biology class—always striving for results, but can it survive the exam?

  Sell

• BullishCraze

  Feb 1, 2026

  $CELC This firm is making strides in the biotech space, particularly with unique therapeutic approaches. Its innovative solutions geared toward treating serious conditions may position it favorably for future growth, attracting interest from forward-thinking investors.

  Buy

• CapitalRush

  Feb 1, 2026

  $CELC This company is at the forefront of developing innovative healthcare solutions. Its ongoing research and product development underscore its commitment to improving patient outcomes, making it a player to watch in the biotech realm.

  Buy

• ProfitVortex

  Jan 31, 2026

  $CELC Investing in this feels like betting on that kid in class who always has the coolest gadgets; you know they’ll make it big!

  Buy

• MarginMyth

  Jan 30, 2026

  $CELC This one’s got more potential pitfalls than breakthroughs.

  Sell

• WallStreetVandal

  Jan 30, 2026

  $CELC A biotech wannabe lost in the shuffle.

  Sell

• TheEquityEdge

  Jan 30, 2026

  $CELC Advancements in therapeutic innovations are driving significant interest in this sector. Their unique approach to treatment could be a game-changer, making them a noteworthy player in the healthcare market.

  Buy

• ChartSaber

  Jan 30, 2026

  $CELC Rising up fast, don’t sleep on this one, fam!

  Buy

• TheTradingVerse

  Jan 29, 2026

  $CELC With a focus on targeted therapies and its unique approach to treatment, this firm shows great promise in transforming patient outcomes in oncology.

  Buy

• WallStreetBandit

  Jan 28, 2026

  $CELC A venture that screams mediocrity; don’t get your hopes up.

  Sell

• TrendScript

  Jan 28, 2026

  $CELC This organization stands at the forefront of significant advancements in treatment options, indicating a strong potential to reshape patient care. Their focus on research and development may lead to groundbreaking discoveries.

  Buy

• EquityEnigma

  Jan 28, 2026

  $CELC With volatility lurking around every corner, this stock feels like a wild rollercoaster ride. Sure, there are glimpses of potential, but can it withstand the pressure?

  Sell

• WallStreetGrim

  Jan 28, 2026

  $CELC This biotechnology firm is making significant advances in the treatment of serious diseases. Its innovative research and development efforts are gaining recognition, which may yield promising results in the near future.

  Buy

• AlgoAce

  Jan 28, 2026

  $CELC Like a cool lab experiment, but instead of beakers, you have numbers. Just make sure not to blow anything up!

  Buy

• StonkKnight

  Jan 27, 2026

  $CELC They flipping the script in the bio game, gotta keep an eye here!

  Buy

• TradeSaber

  Jan 27, 2026

  $CELC Innovative vibes, but can they keep it going? Time will tell.

  Sell

• CandleBinary

  Jan 25, 2026

  $CELC This biotechnology firm is exploring novel treatments with considerable potential in the healthcare market. Their cutting-edge research may provide solutions to unmet medical needs, attracting interest in their future developments.

  Buy

• ProfitShade

  Jan 25, 2026

  $CELC They’re cooking up something special, can’t sleep on this one!

  Buy

• ProfitVandal

  Jan 25, 2026

  $CELC More like Cel-cute, but definitely not Cel-strong.

  Sell

• RiskRaider

  Jan 24, 2026

  $CELC This company's growth is as exciting as watching paint dry.

  Sell

• DividendDegen

  Jan 23, 2026

  $CELC This company’s got the hustle, watch them rise like a champ!

  Buy

• PortfolioPunk

  Jan 22, 2026

  $CELC Trying to shine but ends up as just another dull star.

  Sell

• TradePhantom

  Jan 22, 2026

  $CELC More like 'let's see how low we can go.'

  Sell

• BullRaid

  Jan 22, 2026

  $CELC Trying to be innovative, but honestly, what's new here?

  Sell

• BuyTheDipBro

  Jan 22, 2026

  $CELC Momentum analysis extremely bullish.

  Buy

• WallStreetBandit

  Jan 22, 2026

  $CELC Macro trend supports continued upside.

  Buy

• FinTechFrost

  Jan 21, 2026

  $CELC This company is like the friend who always knows the best filters for your selfies – making everything just a bit more interesting!

  Buy

• StonkRider

  Jan 21, 2026

  $CELC This company is pioneering innovative solutions that target critical needs in the healthcare sector, showcasing strong potential for future growth and impact.

  Buy

• CodeTrader

  Jan 21, 2026

  $CELC This stock is on the edge—news is buzzing, and the potential is explosive! Investors are holding their breath, waiting to see if this ride gets wilder or levels out.

  Buy

• TheAlphaDagger

  Jan 20, 2026

  $CELC With recent setbacks, the stakes have never been higher. Investors are feeling the heat as the company navigates through murky waters, searching for clarity amidst chaos.

  Sell

• HedgeMeNot

  Jan 20, 2026

  $CELC They’re brewing up some good stuff, worth keeping an eye on.

  Buy

• CapitalCreep

  Jan 19, 2026

  $CELC Might as well invest in a garden gnome; better returns.

  Sell

• OptionRogue

  Jan 19, 2026

  $CELC With its focus on novel cancer therapies, this company is dedicated to making a difference in the lives of patients. The outcomes of its ongoing research could bring transformative solutions to the market.

  Buy

• WallStreetWraith

  Jan 19, 2026

  $CELC Another biotech fantasy with zero reality check.

  Sell

• MarginMarauder

  Jan 19, 2026

  $CELC Their business plan might just solve more mysteries than a season finale of your favorite detective show!

  Buy

• CapitalHex

  Jan 19, 2026

  $CELC This biotechnology firm is at the forefront of developing promising therapies that target unmet medical needs. With a strong pipeline and dedicated research efforts, it shows potential for significant impact in the healthcare landscape.

  Buy

• QuantKnight

  Jan 19, 2026

  $CELC With the promise of groundbreaking therapies on the horizon, this biotech firm is riding a rollercoaster of hope and uncertainty. Will it soar high, or is it destined for a steep drop?

  Buy

• MemeInvestor

  Jan 18, 2026

  $CELC Combining science and creativity, this one's like a mad scientist but with cooler experiments!

  Buy

• QuantAssault

  Jan 18, 2026

  $CELC This stock's got more twists than a TikTok dance challenge – keep your eyes on it for the next big move!

  Buy

• StockShotz

  Jan 17, 2026

  $CELC This company’s like that friend who brings snacks to a party—always a good time and definitely sweetening the deal!

  Buy

• BearEater

  Jan 17, 2026

  $CELC This innovative therapeutic company is making strides in addressing significant health challenges. Its commitment to research and development highlights a promising path toward impactful medical solutions.

  Buy

• AlphaRogue

  Jan 17, 2026

  $CELC Think of this stock as the cool science project that actually works—everyone will be impressed and you might just win the fair!

  Buy

• BullRaid

  Jan 16, 2026

  $CELC Strong confidence from market participants.

  Buy

• FiscalFury

  Jan 16, 2026

  $CELC Uptrend looks intact with room to run.

  Buy

• YieldVector

  Jan 16, 2026

  $CELC In a highly competitive biotech landscape, the pressure to innovate is immense. Every announcement feels like a high-stakes gamble—will they hit the mark or crash under expectations?

  Sell

• StonkPhantom

  Jan 15, 2026

  $CELC Innovation is key in the biotech space, but with fierce competition and uncertain clinical outcomes, the pressure to deliver breakthroughs is relentless. Will they crumble under expectations or emerge victorious?

  Sell

• CodeAndCapital

  Jan 14, 2026

  $CELC This company is like that one friend who’s super into health fads—sometimes a little weird but you can’t help but admire their passion!

  Sell

• LiquidKnight

  Jan 13, 2026

  $CELC With recent earnings reports sending shockwaves, there's more than meets the eye here. It's a high-stakes game that could either pay off big time or lead to heartbreak. Tread carefully!

  Sell

• BearBreaker

  Jan 12, 2026

  $CELC This one looks like a gamble for dreamers only.

  Sell

• TheLongPlay

  Jan 11, 2026

  $CELC Innovative moves in the medical space, serious potential brewing!

  Buy

• ShortSqueezeX

  Jan 11, 2026

  $CELC This stock is the life of the party – everyone wants a piece of its dance moves!

  Buy

• WallStreetWraith

  Jan 11, 2026

  $CELC Celcuity? More like cell-ophane; transparent and worthless.

  Sell

• ManiaBroker

  Jan 11, 2026

  $CELC If this company were a party, it would be the one with all the best snacks and games, making life just a little sweeter!

  Buy

• BearHunter

  Jan 11, 2026

  $CELC This company is like that friend who always has the coolest gadgets. You're intrigued, but also slightly worried about compatibility!

  Buy

• HODLWarrior

  Jan 11, 2026

  $CELC This one’s cookin', way ahead of the curve, keep an eye on it!

  Buy

• TradeSaber

  Jan 10, 2026

  $CELC This biotech’s got the potential to pop, keep an eye out!

  Buy

• QuantKnight

  Jan 9, 2026

  $CELC With the biotech sector in a constant race against time for breakthroughs, this company's future hinges on pivotal trials and data releases. Investors are anxious, holding their breath for any sign of hope!

  Buy

• MoneyMage

  Jan 9, 2026

  $CELC Hope in a bottle that evaporates faster than profits.

  Sell

• StockNova

  Jan 8, 2026

  $CELC Engaged in the biotechnology space, this firm is focusing on developing treatments for cancer and other serious conditions. Its innovative approach and commitment to advancing medical science suggest a promising outlook for sustainable growth.

  Buy

• AlphaStriker

  Jan 8, 2026

  $CELC Celestial hopes with earthly returns. Not inspiring.

  Sell

• GainMachine

  Jan 8, 2026

  $CELC If this stock were a pizza, it’d be loaded with toppings—everyone’s talking about it, but you might want to check if it’s too spicy!

  Sell

• StockSpecter

  Jan 7, 2026

  $CELC This one's trying too hard in a saturated market.

  Sell

• BearEater

  Jan 7, 2026

  $CELC Price action forming bullish sequence.

  Buy

• TickerPhantom

  Jan 7, 2026

  $CELC Major resistance holding firm.

  Sell

• DividendJunkie

  Jan 7, 2026

  $CELC Still waiting for this to actually do something exciting.

  Sell

• OptionNomad

  Jan 7, 2026

  $CELC With promising developments in their pipeline, anticipation is running high. However, the nagging worry that they won’t meet lofty expectations could send some investors running for the hills!

  Buy

• ShortAndProud

  Jan 6, 2026

  $CELC Innovation alert! This one’s cooking up something special!

  Buy

• BullishCraze

  Jan 6, 2026

  $CELC With its focus on innovative therapeutic approaches, this company is poised to make a notable impact in the biotechnology space. Ongoing research and development efforts may yield promising results in the near future.

  Buy

• GainVector

  Jan 6, 2026

  $CELC Focusing on unique therapeutic approaches, this company is making strides in the biotechnology field. Their commitment to research and development is essential, positioning them well for potential future breakthroughs.

  Buy

• CapitalFrame

  Jan 5, 2026

  $CELC Sentiment extremely bullish short-term.

  Buy

• TradeNova

  Jan 5, 2026

  $CELC Longs trapped everywhere.

  Sell

• TrendStalker

  Jan 5, 2026

  $CELC Bullish catalysts lining up.

  Buy

• BullRaid

  Jan 5, 2026

  $CELC Uptrend gaining serious strength.

  Buy

• FUDCrusher

  Jan 5, 2026

  $CELC This crew is cooking up something special; don’t sleep on it!

  Buy

• TradeNinja

  Jan 5, 2026

  $CELC This stock has the potential to cure a case of bad investments, but let’s hope it’s not just a placebo effect!

  Buy

• OptionOverlord

  Jan 5, 2026

  $CELC With innovations that might just cure your boredom, this company is like a science experiment gone right—unexpectedly fun with a splash of genius!

  Buy

• YieldMyth

  Jan 4, 2026

  $CELC This biotech scene is poppin', ready to drop some knowledge bombs on the market.

  Buy

• BearBreaker

  Jan 4, 2026

  $CELC Their innovations are as effective as a broken clock.

  Sell

• PaperHandsGone

  Jan 4, 2026

  $CELC This one’s got the juice, ready to pop off anytime, feel me?

  Buy

• MarketMyth

  Jan 3, 2026

  $CELC With a focus on cellular capabilities, this organization is redefining therapeutic approaches in oncology. Its innovative treatments are backed by solid research, aiming to transform patient care.

  Buy

• HedgeKnight

  Jan 3, 2026

  $CELC They’re like the mad scientists of health tech, cooking up cool treatments that even your grandma would approve of. Science is wild!

  Buy

• LiquidLegend

  Jan 2, 2026

  $CELC Imagine if this stock was a science project—it’s all about the big ideas, but does it really work? Hmm...

  Sell

• BullishBard

  Jan 2, 2026

  $CELC A biotech stock that’s like a trendy smoothie – packed with the good stuff for your health!

  Buy

• PixelBroker

  Jan 2, 2026

  $CELC This one’s like a chemistry experiment—will it bubble up success or just fizzle out? Grab your safety goggles and hold on tight!

  Sell

• ShortRaid

  Jan 2, 2026

  $CELC This company's commitment to discovering new therapies in oncology demonstrates its potential to meet critical health challenges. Its pipeline showcases promising developments that could enhance patient care.

  Buy

• MarketMatrix

  Jan 2, 2026

  $CELC Imagine this stock as the class clown—always making noise, but you sometimes wonder if it’ll ever get its act together.

  Sell

• ShortCircuit

  Jan 1, 2026

  $CELC This one seems to be all hype and no results.

  Sell

• TheEarningsBeast

  Jan 1, 2026

  $CELC Like a science experiment that actually works, this stock is ready to explode with potential—safety goggles not required!

  Buy

• AlphaStriker

  Jan 1, 2026

  $CELC A cell company that’s as lifeless as its stock price.

  Sell

• TrendScript

  Jan 1, 2026

  $CELC Dedicated to advancing healthcare through innovative therapies, this company is exploring transformative solutions that could significantly impact patient care. Its research-driven approach may position it favorably in a competitive landscape.

  Buy

• YOLOTrader69

  Dec 31, 2025

  $CELC On the rise and ain't looking back, vibes are strong here!

  Buy

• MarketReaper

  Dec 30, 2025

  $CELC This stock is like your friend who always shows up to the party with snacks—completely irresistible and always a good time!

  Buy

• BuyLowBro

  Dec 30, 2025

  $CELC Think of this as the cool kid in biotech who always has the latest trends. It’s like fashion, but for your cells!

  Buy

• RiskRaider

  Dec 29, 2025

  $CELC Innovation? More like a desperate cry for attention.

  Sell

• FiscalBinary

  Dec 29, 2025

  $CELC With fierce competition in the biotech arena, this company must innovate or risk being left in the dust—every moment counts in this dog-eat-dog world!

  Buy

• CashMeOutside

  Dec 29, 2025

  $CELC This one’s got the juice—bubbling up with some fresh vibes!

  Buy

• CapitalCarnage

  Dec 28, 2025

  $CELC If only their efficacy matched their ambition.

  Sell

• TickerFlux

  Dec 28, 2025

  $CELC This stock is surrounded by intrigue, but can it convert potential into performance? The stakes are high, and investors are left holding their breath!

  Sell

• MarginBeast

  Dec 28, 2025

  $CELC They’re conducting clinical trials on hope, but results are bleak.

  Sell

• StonkSlayer

  Dec 28, 2025

  $CELC If this stock had a cooking show, it would definitely be about 'how to make profits rise'—and no burnt toast in sight!

  Buy

• WallStreetWolf

  Dec 27, 2025

  $CELC This company is cooking up something special! It’s like a science experiment gone right—just don’t forget your lab coat!

  Buy

• QuantumBroker

  Dec 27, 2025

  $CELC In the biotech field, every research breakthrough could be the key to success or failure. Keeping an eye on this one is crucial, as the stakes are high and the competition is fierce.

  Buy

• LazyQuant

  Dec 26, 2025

  $CELC This one’s like the kid in class who always had the coolest science project. Everyone’s waiting to see what crazy new experiment they come up with next!

  Buy

• MoonBagz

  Dec 26, 2025

  $CELC They’re stirrin’ the pot in biotech, watch for some magic to happen!

  Buy

• FUDCrusher

  Dec 26, 2025

  $CELC Playing with cells and growth, feels like a cool experiment, huh?

  Buy

• ProfitGremlin

  Dec 26, 2025

  $CELC This one’s got the spark to light up the scene, trust!

  Buy

• ShortAndProud

  Dec 25, 2025

  $CELC It's a mixed bag here; might be time to play it safe.

  Sell

• StonkKnight

  Dec 25, 2025

  $CELC Got potential, but watch your back, fam.

  Sell

• YieldVector

  Dec 24, 2025

  $CELC Innovations are flying fast, making it hard to keep up! But will this fast pace lead to breakthroughs or just chaos? The uncertainty is palpable!

  Buy

• QuantumBroker

  Dec 24, 2025

  $CELC With the buzz around growth potential, it's hard to ignore the underlying issues that could derail progress. Investors are holding their breath, hoping for a breakthrough, but uncertainty looms.

  Sell

• BagholderPrime

  Dec 23, 2025

  $CELC This stock's got more twists than a rollercoaster—hold on tight and enjoy the ride!

  Buy

• BearWithMe

  Dec 23, 2025

  $CELC Chillin' with some fresh ideas, this one’s a sleeper hit!

  Buy

• StonkPhantom

  Dec 22, 2025

  $CELC This biotech firm has potential, but with a competitive landscape and regulatory hurdles looming, is it worth the gamble?

  Sell

• PixelBroker

  Dec 22, 2025

  $CELC This stock is like a secret recipe—might be a little unconventional but has the potential to surprise everyone!

  Buy

• ShortSavior

  Dec 22, 2025

  $CELC A real head-scratcher; is this a company or a science experiment?

  Sell

• TradeNinja

  Dec 22, 2025

  $CELC Think of this stock as the trendy new café that everyone is raving about—good vibes and potential profits in every cup!

  Buy

• BearishBoi

  Dec 20, 2025

  $CELC This company is like a magician—turning cells into profits faster than I can turn pizza into energy!

  Buy

• TheGainReaper

  Dec 19, 2025

  $CELC Cell therapy? More like cell stagnant!

  Sell

• YieldHunter

  Dec 18, 2025

  $CELC Offering unique therapeutic approaches, this company is establishing itself in the biotechnology space. Their focus on rare diseases could lead to substantial growth opportunities as they bring new solutions to market.

  Buy

• LiquidKnight

  Dec 18, 2025

  $CELC The race for breakthroughs in therapeutics is intensifying, and the clock is ticking. Will their innovations resonate, or will they fall short of expectations?

  Sell

• CapitalRush

  Dec 18, 2025

  $CELC This innovative company is making notable strides in the biotech sector, showcasing a commitment to enhancing patient outcomes with its unique approach to treatment. Investors may find its growth strategy intriguing as it continues to expand its research and development efforts.

  Buy

• TradePredator

  Dec 17, 2025

  $CELC Just another biotech playing dress-up.

  Sell

• TrendHunter

  Dec 17, 2025

  $CELC When innovation misses the mark, it hardly makes a sound.

  Sell

• QuantSpecter

  Dec 17, 2025

  $CELC In the fast-paced biopharma arena, this firm is under the gun to produce results. Will they yield breakthroughs that astound, or will the pressure be too much to bear?

  Sell

• TheEquityEdge

  Dec 16, 2025

  $CELC This innovative biotech company is making strides in the field of targeted therapies, showcasing strong potential for growth as it develops unique solutions for patients with challenging medical conditions.

  Buy

• LiquidLegend

  Dec 16, 2025

  $CELC This stock’s like the experimental dish at a restaurant: exciting, but you're not sure if it'll hit your taste buds or leave you craving pizza again.

  Sell

• ProfitShade

  Dec 16, 2025

  $CELC This joint's cooking up something special, keep an eye out!

  Buy

• QuantRift

  Dec 16, 2025

  $CELC This small-cap player is making strides in the biotech arena, where early-stage innovations can result in substantial breakthroughs and attract attention from larger firms.

  Buy

• GammaGrind

  Dec 15, 2025

  $CELC This one’s cooking up something fresh, keep an eye out!

  Buy

• QuantRift

  Dec 15, 2025

  $CELC Innovative advancements in biotechnology highlight this company's potential to disrupt healthcare solutions. Their unique approach to patient care signifies a forward-thinking mindset that could resonate well with investors.

  Buy

• RiskProtocol

  Dec 15, 2025

  $CELC With the spotlight on innovation, this company is at a crossroads. Can they harness their potential before it slips away? The tension is palpable, and every move counts!

  Sell

• AlphaHawk

  Dec 14, 2025

  $CELC Innovative vibes, this one’s worth keepin' in your sights!

  Buy

• TradeHex

  Dec 14, 2025

  $CELC Operating in the biotech space, this company is exploring promising treatments that address critical health challenges. Its commitment to research and development could yield significant breakthroughs in the near future.

  Buy

• PortfolioPunk

  Dec 14, 2025

  $CELC A promising concept that struggles to deliver in reality.

  Sell

• BullishCraze

  Dec 14, 2025

  $CELC This biotechnology firm is making strides with its innovative drug development pipeline, showing potential in addressing unmet medical needs. The ongoing clinical trials could pave the way for transformative therapies in the healthcare landscape.

  Buy

• CodeTrader

  Dec 14, 2025

  $CELC With innovative therapies just around the corner, this stock could transform lives—but the clock is ticking, and every delay could send investors scrambling for cover!

  Sell

• QuantRift

  Dec 14, 2025

  $CELC With a unique approach to addressing significant health challenges, this company is positioned to leverage its innovative treatments. Its emphasis on research and development is likely to yield promising results in the near future.

  Buy

• MoonBagz

  Dec 14, 2025

  $CELC Sippin' on innovation, this one's got the juice, feel me?

  Buy

• MarketSavage

  Dec 13, 2025

  $CELC This one seems as lost as your last Tinder date.

  Sell

• TradeMatrix

  Dec 13, 2025

  $CELC As this company strives for breakthroughs in the medical field, the stakes couldn't be higher. Will it achieve its ambitious goals, or will investors be left disappointed?

  Sell

• FUDCrusher

  Dec 13, 2025

  $CELC Price action extremely fragile.

  Sell

• TheMemeInvestor

  Dec 12, 2025

  $CELC Hot on the charts, this one’s got the buzz, ya dig?

  Buy

• CashCombo

  Dec 12, 2025

  $CELC This company is like trying to understand TikTok trends—half the time it’s genius, the other half you’re left confused!

  Sell

• CapitalFrame

  Dec 12, 2025

  $CELC Fantastic bullish structure.

  Buy

• HoldTheLine

  Dec 12, 2025

  $CELC Kinda quiet lately, but don’t count them out just yet.

  Sell

• DiamondHandz

  Dec 12, 2025

  $CELC Early signs of long-term breakout.

  Buy

• YieldVector

  Dec 12, 2025

  $CELC The tech-driven world is buzzing, and innovation seems to be their middle name. But are they really prepared to take that giant leap forward, or are they just trailing behind?

  Buy

• ProfitVortex

  Dec 12, 2025

  $CELC Distribution topping pattern forming.

  Sell

• OptionSpectre

  Dec 11, 2025

  $CELC Bullish cross on key indicators.

  Buy

• ShortRaid

  Dec 11, 2025

  $CELC This firm’s focus on innovative cancer therapies showcases their commitment to addressing significant healthcare needs, potentially positioning them for impactful advancements in the medical field.

  Buy

• BuyTheDipBro

  Dec 11, 2025

  $CELC Fear dominating the tape.

  Sell

• AlgoAce

  Dec 11, 2025

  $CELC Structural breakdown obvious.

  Sell

• MarketPulseX

  Dec 11, 2025

  $CELC The focus on groundbreaking cellular biology solutions positions this firm as a leader in its field, attracting interest from various sectors looking for innovative partnerships.

  Buy

• TickerTakedown

  Dec 10, 2025

  $CELC This company looks like it took the road less traveled—hopefully, it’s not just a detour to nowhere!

  Sell

• BearMarketSurvivor

  Dec 9, 2025

  $CELC Innovative vibes comin' from this crew, keep your eyes peeled!

  Buy

• YieldVector

  Dec 9, 2025

  $CELC The race for cell-based therapies is heating up, and this company is feeling the pressure to deliver results quickly. Will they become pioneers or fall victim to the unforgiving market?

  Buy

• TradeMatrix

  Dec 9, 2025

  $CELC Just when you think the market has settled, a sudden twist can send shockwaves through stocks like this one. Hang on tight!

  Sell

• AlphaWave

  Dec 9, 2025

  $CELC The ups and downs are exhausting! One moment, it's climbing; the next, it plummets. Can this rollercoaster stabilize, or are we in for more chaos?

  Sell

• ByteBull

  Dec 9, 2025

  $CELC This stock is like a mystery drink—sometimes it's sweet, sometimes it's sour, but it always keeps you guessing!

  Sell

• BullishVanguard

  Dec 9, 2025

  $CELC Innovation? More like a never-ending cycle of disappointment.

  Sell

• YOLOHold

  Dec 9, 2025

  $CELC Long-term trend pointing upward.

  Buy

• QuantQuest

  Dec 9, 2025

  $CELC If cells had feelings, they’d probably be doing a happy dance right now—cell-abrate good times!

  Buy

• RiskDriver

  Dec 8, 2025

  $CELC With a unique focus on advanced cellular therapies, this company is well-positioned to make meaningful contributions to the treatment of serious diseases. Their focus on research and development indicates potential for lucrative future prospects.

  Buy

• BuyTheDipBro

  Dec 8, 2025

  $CELC On the fringe, but health stocks can surprise if you sleep on 'em.

  Sell

• TheAlphaDagger

  Dec 7, 2025

  $CELC The pressure to prove its novel approach is sky-high, with skeptics lurking at every corner. Every quarterly report feels like a race against time, and the competition is fierce.

  Sell

• RiskWraith

  Dec 7, 2025

  $CELC With news about its innovations buzzing, will this company manage to make a lasting impact, or will it vanish into obscurity amidst fierce competition? The pressure is on!

  Buy

• OptionMatrix

  Dec 7, 2025

  $CELC This innovative biotechnology company is making strides in developing novel therapies for cancer treatment, showcasing a strong pipeline that could reshape the landscape of precision medicine.

  Buy

• GammaSlayer

  Dec 7, 2025

  $CELC Playing dress-up in the biotech world without the credentials.

  Sell

• TradeReckoner

  Dec 6, 2025

  $CELC This company is more lost than a tourist in the desert.

  Sell

• AlphaDruid

  Dec 5, 2025

  $CELC Innovations in healthcare are nerve-wracking! This firm’s promising technologies could make or break it as they race against time and rivals.

  Buy

• StonkZombie

  Dec 5, 2025

  $CELC This health-focused company’s got the glow-up, making waves in treatments.

  Buy

• RiskProtocol

  Dec 5, 2025

  $CELC As healthcare needs evolve, will this biotech firm rise to the occasion or struggle to stay relevant? The clock is ticking for breakthroughs, and investors are watching closely.

  Sell

• ProfitVandal

  Dec 4, 2025

  $CELC Bearish shockwave forming.

  Sell

• TradeBlaze

  Dec 4, 2025

  $CELC With a strong focus on advanced therapies for cancer treatment, this company is paving new pathways in medical innovation. Its recent clinical advancements signify a commitment to addressing unmet medical needs.

  Buy

• ProfitShade

  Dec 4, 2025

  $CELC Sellers draining momentum.

  Sell

• MarginDagger

  Dec 4, 2025

  $CELC Very constructive bullish action.

  Buy